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Abstract
Rationale—Stimulant medications for Attention-Deficit/Hyperactivity Disorder (ADHD) in 
adolescents remains controversial with respect to later development of cocaine abuse. Past 
research demonstrated that adolescent methylphenidate treatment increased several aspects of 
cocaine self-administration during adulthood using the Spontaneously Hypertensive Rat (SHR) 
model of ADHD. Presently, we determined effects of the alternate stimulant medication, d-
amphetamine, on cocaine self-administration.
Objectives—We tested the hypothesis that adolescent d-amphetamine would not increase 
cocaine self-administration in adult SHR, given that d-amphetamine has a different mechanism of 
action than methylphenidate.
Methods—A pharmacologically relevant dose of d-amphetamine (0.5 mg/kg) or vehicle was 
administered throughout adolescence to SHR and two control strains, Wistar-Kyoto (WKY) and 
Wistar (WIS). Three aspects of cocaine abuse vulnerability were assessed in adulthood after 
discontinuing adolescent treatments: acquisition rate and dose-related responding under fixed (FR) 
and progressive (PR) ratio schedules.
Results—Adult SHR acquired cocaine self-administration faster and self-administered more 
cocaine across multiple doses compared to WKY and WIS under FR and PR schedules, indicating 
SHR is a reliable animal model of comorbid ADHD and cocaine abuse. Relative to vehicle, SHR 
and WIS with adolescent d-amphetamine treatment self-administered less cocaine upon reaching 
acquisition criteria, and WIS additionally acquired cocaine self-administration more slowly and 
had downward shifts in FR and PR cocaine dose-response curves. WKY with adolescent d-
amphetamine treatment acquired cocaine self-administration more quickly relative to vehicle.
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Conclusions—In contrast to methylphenidate, adolescent d-amphetamine did not augment 
cocaine self-administration in SHR. Adolescent d-amphetamine treatment actually protected 
against cocaine abuse vulnerability in adult SHR and WIS.
Keywords
Adolescence; Attention deficit/hyperactivity disorder; Cocaine self-administration; d-
Amphetamine; Spontaneously Hypertensive Rat
Introduction
Adolescents and adults with non-medicated ADHD have 2-3 times greater use of cocaine, 
other stimulants, tobacco, and marijuana compared to controls without ADHD (Lee et al. 
2011). Over the years, a number of investigators have examined the relationships between 
stimulant medication for childhood ADHD and vulnerability to cocaine and other substance 
use disorders (SUD) during adolescence or adulthood. The first meta-analysis examining 
this question in ADHD patients concluded that stimulant medication in childhood is 
associated with reduced SUD risk during adolescence and young adulthood (Wilens et al. 
2003). This stance regarding protective effects of stimulant medications has shifted over the 
years, with the most recent meta-analysis and another broadly conducted study in ADHD 
patients concluding that stimulant medication in childhood neither protects against nor 
increases later SUD risk (Humphreys et al. 2013; Molina et al. 2013). While this is good 
news, caution should be exercised in generalizing these findings beyond the initiation of 
medication during childhood. A concern may arise when stimulant treatment begins during 
adolescence, as the later the initiation in childhood, the greater the risk of developing SUD 
(Dalsgaard et al. 2014; Lambert et al. 1998; Manuzza et al. 2008; Steinhausen and Bisgaard, 
2014). Evaluation of long-term effects of stimulant medications on SUD has been 
complicated by difficulty in controlling certain variables in human populations, such as 
presence of comorbid conduct disorder, precise age of treatment initiation, and duration of 
untreated symptoms (Steinhausen and Bisgaard, 2014). Moreover, clinical studies rarely 
distinguish between different stimulant medications in ADHD, which have different 
mechanisms of action and potentially different long-term neurochemical consequences. To 
more closely and systematically examine the relationships between adolescence stimulant 
medication and cocaine abuse vulnerability, we conduct preclinical studies using SHR, the 
most widely studied animal model of ADHD (Russell 2011). We employ Wistar-Kyoto 
(WKY) and Wistar (WIS) rats as inbred and outbred control strains, respectively. The WKY 
controls for the genetic homogeneity of the SHR (Russell 2011), but also has been used to 
model depressive, anxious, and autism-related phenotypes (Paré et al. 1997; Zhang-James et 
al. 2014). WIS is a common ancestor to both WKY and SHR and represents the genetic 
variance of a normative population.
SHR exhibit core behavioral and cognitive symptoms of ADHD, including hyperactivity, 
impulsivity, and inattention (Adriani et al. 2003; Bayless et al. 2015; Hill et al. 2012; 
Sagvolden et al. 2000; Somkuwar et al. 2016). SHR also model neurobiological 
abnormalities observed in ADHD, including greater striatal dopamine transporter density 
(Roessner et al. 2010; Silva et al. 2014). Notably, SHR have elevated cocaine self-
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administration (Baskin et al. 2015; Harvey et al. 2011; Jordan et al. 2014; 2016; Somkuwar 
et al. 2013b), consistent with the known comorbidity between ADHD and cocaine abuse 
(Lee et al. 2011). Moreover, treatment with a pharmacologically relevant dose of 
methylphenidate during adolescence further increases several aspects of cocaine self-
administration in SHR during adulthood (see below) without altering cocaine self-
administration behavior in WKY and WIS controls (Baskin et al. 2015; Harvey et al. 2011; 
Jordan et al. 2014). Mechanistically, methylphenidate inhibits dopamine and norepinephrine 
transporters (DAT and NET, respectively), reducing neurotransmitter uptake into nerve 
terminals (Sulzer et al. 2005). One potential mechanism by which adolescent 
methylphenidate may uniquely augment cocaine self-administration in SHR is by increasing 
DAT function in medial prefrontal cortex (mPFC; Somkuwar et al. 2013a).
Alternative medications for teenagers with ADHD may be needed given findings with 
methylphenidate in SHR. As non-stimulant medications are not as clinically efficacious as is 
methylphenidate for ADHD symptoms (Sibley et al. 2014), the current study determined 
whether or not the alternative stimulant medication d-amphetamine would increase cocaine 
self-administration behaviors in the SHR model of ADHD. We selected d-amphetamine 
because it is the active agent in Dexedrine®, Adderall®, and Vyvanse®, the three most 
commonly prescribed amphetamine formulations for ADHD worldwide (Heal et al. 2013). 
Notably, the d-isomer of amphetamine is more efficacious than the l-isomer in alleviating 
ADHD symptoms (Arnold et al. 1973) and in modulating dopamine activity (Patrick and 
Morowitz 1997). Although both d-amphetamine and methylphenidate increase extracellular 
dopamine and norepinephrine, these drugs act via different primary mechanisms. Unlike 
methylphenidate, d-amphetamine is a substrate at DAT and NET, reversing neurotransmitter 
transport from inside the neuron terminal to the extracellular space, in addition to being a 
substrate at serotonin and vesicular monoamine-2 transporters (Sulzer et al. 2005). 
Importantly, d-amphetamine decreases DAT function in nucleus accumbens of adult outbred 
rats (Ferris et al. 2015). Thus, we hypothesized that adolescent d-amphetamine would not 
increase cocaine self-administration behaviors in adulthood in the SHR model. Previously, 
we reported that d-amphetamine (0.5 mg/kg) had procognitive effects in adolescent SHR, 
and that after discontinuing treatment in adulthood, cocaine seeking and reactivity to cocaine 
cues were not increased under a second-order schedule of cocaine delivery and cue 
presentation (Jordan et al. 2016). In comparison, adolescent methylphenidate increased 
cocaine self-administration, but not reactivity to cocaine cues, under the same second-order 
schedule in adult SHR (Jordan et al. 2014). We also reported that in adult SHR, adolescent 
methylphenidate increased the rate of acquisition of cocaine self-administration and 
enhanced the reinforcing effects of cocaine studied under FR and PR schedules (Baskin et 
al. 2015; Harvey et al. 2011). These measures model the early phases of cocaine use and 
identify phenotypes that are most vulnerable to developing addiction or dependence (Piazza 
et al. 2000). The current study therefore investigated these important aspects of cocaine 
abuse vulnerability following treatment with a pharmacologically relevant dose of d-
amphetamine.
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Materials and methods
Subjects and adolescent drug treatments
Male WKY/Cr, WIS/Cr, and SHR/Cr rats (Charles River Laboratories, USA) arrived on 
postnatal day 25 (P25) and were individually housed in a temperature- (21–23°C) and light- 
(07:30 h on; 19:30 h off) controlled vivarium. To minimize potential litter effects, two 
cohorts of animals were procured 6 months apart; each cohort consisted of 6-10 rats/strain. 
Additionally, animals were randomly assigned to a treatment group upon arrival, with VEH 
and AMPH treatments alternating between rats within each cohort. From P28-P55, food was 
restricted to ~90% of a growth-adjusted free-feeding body weight specific for each strain to 
mimic the feeding schedule used in our prior comparator studies (Harvey et al. 2011; Jordan 
et al. 2014; 2016; Somkuwar et al. 2013b). Animals had free access to water, and food was 
unrestricted after P55. On P77, when animals began cocaine self-administration (see 
Experiment 1), body weights were as follows: VEH WKY 255 ± 5 g, AMPH WKY 254 ± 5 
g, VEH WIS 356 ± 11 g, AMPH WIS 359 ± 8 g, VEH SHR 238 ± 3 g, and AMPH SHR 240 
± 6 g. All procedures were approved by the Boston University Institutional Animal Care and 
Use Committee and in accordance with the National Institutes of Health Guide for the Care 
and Use of Laboratory Animals (8th Edition).
For adolescent treatment, we selected a dose of 0.5 mg/kg d-amphetamine hemisulfate salt 
(AMPH; Sigma-Aldrich, St. Louis, MO, USA), which was dissolved in sterile 0.9% saline 
and injected intraperitoneally (i.p.) in a volume of 2 ml/kg. This dose increases prefrontal 
cortex (PFC) catecholamines without inducing locomotor hyperactivity when administered 
to young animals (Heitjz et al. 2003; Solanto 2000; Tanda et al. 1997). The oral dose range 
(salt weights) prescribed to individuals with ADHD is 0.1 - 0.7 mg/kg/day (Wilkes et al. 
2015). After administration of 0.5 mg/kg AMPH, plasma levels peak at 60 ng/ml (adult rats) 
and 85 ng/ml (juvenile rats) after i.p and subcutaneous injection, respectively (Heijtz et al. 
2003; West et al. 1999), which corresponds to the range of plasma levels found in children 
with ADHD after oral AMPH treatment (64-84 ng/mL, Brown et al. 1979). A main 
difference is that the half-life of AMPH is shorter in rats (~1 h) than in children (6-7 h). The 
i.p. route of administration for AMPH was used due to low oral bioavailability in the rat 
(Beránková et al. 2007; Kuczenski and Segal, 2001). Sterile 0.9% saline injections (2 ml/kg) 
served as vehicle (VEH) control. Treatments were administered once daily, Monday-Friday 
during adolescence (P28-P55, Spear 2000). This schedule mimics the weekend medication 
“holiday” often elected by ADHD patients (Martins et al. 2004). AMPH treatment was 
discontinued on P56.
Experiment 1: Acquisition of cocaine self-administration
This experiment evaluated acquisition of cocaine self-administration under a FR schedule in 
adult WKY, WIS, and SHR treated during adolescence with AMPH or VEH. The operant 
chambers used for self-administration sessions and the procedures for catheter implantation 
on P67 and catheter maintenance were described previously (Jordan et al. 2016). On P77, 
rats (n = 8/strain and treatment group) were allowed to press the active lever (designated left 
or right, counterbalanced across animals) to earn a 0.3 mg/kg cocaine infusion under a FR1 
schedule of reinforcement. The alternate lever was designated the inactive lever for which 
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responses were recorded, but had no consequences, throughout the sessions. Cocaine 
hydrochloride (NIDA, Bethesda, MD, USA) was dissolved in sterile 0.9% saline containing 
3 IU/ml heparin. The training dose was 0.3 mg/kg (a 0.8 mg/ml concentration infused at a 
rate of 1.8 ml/min for a duration of 1.2s/100 g body weight). The 0.3 mg/kg training dose 
was selected because it maintains moderate rates of responding under an FR1 schedule from 
which increases and decreases in responding can be detected (Harvey et al. 2011; Somkuwar 
et al. 2013). The concentration of cocaine was adjusted to keep infusion parameters constant 
across doses. Infusions coincided with extinguishing of the house light and illumination of 
the stimulus light above the active lever for a 20 s timeout period, during which additional 
cocaine infusions could not be earned with an active lever press. Animals did not receive any 
external inducements to lever press (i.e., no prior lever press training and no lever baiting). 
All sessions were 2 h and occurred once daily, Monday-Friday, during the light phase. The 
number of sessions required to reach the acquisition criterion was recorded. The acquisition 
criterion was defined as ≥ 20 infusions in 2 h for two consecutive sessions and a ratio of at 
least 2:1 active to inactive lever responses. These procedures are identical to those used to 
determine the effects of adolescent methylphenidate (Harvey et al. 2011) and the non-
stimulant atomoxetine (Somkuwar et al. 2013b) on acquisition of cocaine self-administration 
in SHR, WKY and WIS. Animals transitioned to Experiment 2 immediately upon reaching 
the acquisition criterion in Experiment 1, which occurred between P79 and P102 in 
individual rats.
Experiment 2: Fixed ratio cocaine dose-response functions
Following Experiment 1, the same rats continued to self-administer 0.3 mg/kg cocaine under 
a FR1 20-s timeout schedule until responding and cocaine intake varied <15% for 5 
consecutive 2 h sessions (Monday-Friday). The reinforcing effects of cocaine then were 
evaluated across a range of doses under this schedule in adult WKY, WIS, and SHR treated 
during adolescence with AMPH or VEH. This experiment used procedures identical to those 
determining the effects of adolescent methylphenidate (Harvey et al. 2011) and atomoxetine 
(Somkuwar et al. 2013b) on FR cocaine dose-response functions in SHR, WKY and WIS. 
Dose-response functions were generated by substituting various cocaine test doses (0.003, 
0.01, 0.03, 0.1, and 1.0 mg/kg) in pseudo-random order, every Tuesday, Thursday, and 
Friday. Each test dose was evaluated in 2-3 sessions, or until no upward or downward trends 
in responding were observed. The 0.3 mg/kg dose was available on intervening days, and for 
2-3 days after completion of the dose-response curve. One VEH- and one AMPH-treated 
SHR died prior to completing Experiment 2, resulting in n = 7-8/strain and treatment group. 
Animals transitioned to Experiment 3 immediately upon completing FR1 dose-response 
testing in Experiment 2, which occurred between P112 and P140 in individual rats.
Experiment 3: Progressive ratio cocaine dose-response functions
Following Experiment 2, the reinforcing effects of cocaine were evaluated across a range of 
doses under a PR schedule in the same rats treated during adolescence with AMPH or VEH 
and used in Experiments 1 and 2. This experiment used procedures identical to those 
determining the effects of adolescent methylphenidate (Harvey et al. 2011) and atomoxetine 
(Somkuwar et al. 2013b) on PR cocaine dose-response functions in SHR, WKY and WIS. 
The PR schedule involved a geometric increment in the number of responses required to 
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earn each successive cocaine infusion (Loh and Roberts 1990). A 20-s timeout also was 
used. PR breakpoint was defined as the number of infusions earned as well as the last FR 
completed to earn a cocaine infusion. Sessions terminated when a rat failed to reach the next 
response requirement within 1 h of the previous infusion, or when 4.5 h elapsed, whichever 
occurred first. Rats self-administered 0.3 mg/kg cocaine under the PR schedule until 
performance varied <15% for 5 consecutive sessions (Monday-Friday). Cocaine test doses 
(0.01, 0.1, 0.3, and 1.0 mg/kg) were then substituted in descending order, with 2-3 
consecutive sessions for each test dose. One VEH- and one AMPH-treated WKY and one 
AMPH-treated SHR died prior to completing Experiment 3, resulting in n = 6-8/strain and 
treatment group. Animals were euthanized upon completing PR dose-response testing in 
Experiment 3, which occurred between P140 and P165 for individual rats.
Data analysis
The primary dependent measures were the number of sessions required to spontaneously 
acquire cocaine self-administration to criterion levels (square root transformed prior to 
analysis due to non-normality) and the number of cocaine infusions earned. Additional 
dependent measures included active and inactive lever responses, and the last FR completed 
under the PR schedule. Although a FR1 schedule was used in Experiments 1 and 2, the 
number of cocaine infusions and active lever responses were analyzed as separate measures 
because the ratio of active responses to infusions was greater than 1:1. This effect was due to 
the 20-s timeout that followed each cocaine infusion, during which animals could respond 
on the active lever, but additional cocaine infusions could not be earned. Thus, active lever 
responses during the timeout period were analyzed as an additional dependent measure in 
Experiments 1 and 2. For Experiment 1, the number of infusions and lever responses 
reported in the results were taken from the session during which rats met the acquisition 
criterion and is referred to as the post-acquisition time point. For Experiment 3, it should be 
noted that the number of infusions is considered to be a better measure of breakpoint than 
last FR completed because it is a continuous rather than a discrete variable (Richardson and 
Roberts 1996). All dependent measures were analyzed using two-factor (strain × treatment) 
and three-factor (strain × treatment × dose) ANOVAs, with repeated measures for dose. For 
all significant main and interaction effects, the Tukey-HSD procedure was used for post-hoc 
pairwise comparisons. To better delineate treatment differences within each strain in cases 
where the treatment main effect was significant, but the strain × treatment or the strain × 
treatment × dose interaction was not, t-tests with Bonferroni correction were used for post-
hoc pairwise comparisons of cell means. In addition, effect sizes (eta squared) were 
computed for significant ANOVA factors. As described by Cohen (1988), effect sizes can be 
characterized as small (η2 = 0.01), medium (η2 = 0.06), or large (η2 = 0.14). Accordingly, 
the majority of effect sizes in the current study were in the medium to large range.
Results
Experiment 1: Acquisition of cocaine self-administration
Individual rats met the acquisition criterion after a minimum of 2 and a maximum of 25 
sessions. Analysis of the number of sessions required to reach the acquisition criterion 
(Figure 1a) identified strain differences [F (2, 42) = 14.7, p<0.001, η2= 0.4] and a strain × 
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treatment interaction [F (2, 42) = 6.6, p<0.003, η2= 0.2]. The main effect of treatment did 
not reach statistical significance (p<0.5). Pairwise comparisons revealed that, overall, SHR 
acquired cocaine self-administration faster (fewer sessions) than WKY and WIS (ps<0.03). 
Moreover, both VEH- and AMPH-treated SHR acquired cocaine self-administration faster 
than VEH- and AMPH-treated WKY and WIS, respectively (ps<0.03). After adolescent 
AMPH treatment, acquisition was slower in adult WIS (p<0.004) and faster in adult WKY 
(p<0.04) compared to VEH in each strain. Adolescent AMPH treatment did not significantly 
alter the rate of acquisition compared to VEH in adult SHR.
Analysis of the number of cocaine infusions earned at the post-acquisition time point (Figure 
1b) revealed strain [F (2, 42) = 16.4, p<0.001, η2=0.4] and treatment [F (2, 42) = 9.1, 
p<0.004, η2= 0.1] differences. The strain × treatment interaction did not reach statistical 
significance (p<0.08). Pairwise comparisons revealed that, overall, SHR earned a greater 
number of cocaine infusions than WKY and WIS (p<0.001 and 0.03, respectively) and that 
WIS earned a greater number of infusions than WKY (p<0.008). Moreover, there were fewer 
cocaine infusions post-acquisition after adolescent AMPH than VEH treatment (p<0.005). 
This effect of adolescent AMPH was detected only in SHR and WIS (ps< 0.016).
Analysis of total active lever responses at the post-acquisition time point (Table 1) revealed 
strain [F (2, 42) = 10.5, p<0.001, η2= 0.3] and treatment [F (1, 42) = 6.2, p<0.01, η2= 0.08] 
differences. The strain × treatment interaction did not reach statistical significance (p<0.08). 
Pairwise comparisons revealed that, overall, SHR made a greater number of active lever 
responses than WKY and WIS (ps<0.001 and 0.01, respectively). Moreover, there were 
fewer active lever responses after adolescent AMPH than VEH treatment (p<0.01). This 
effect of adolescent AMPH was detected only in SHR (p< 0.016). Analysis of timeout 
responses on the active lever at the post-acquisition time point (Table 1) also revealed a 
strain difference [F (2, 42) = 5.4, p<0.008, η2=0.2], but there was no significant influence of 
treatment, either as a main effect (p<0.09) or as an interaction with strain (p<0.11). Pairwise 
comparisons revealed that, overall, SHR made more timeout responses on the active lever 
than WKY (p<0.009) or WIS (p<0.04). For total inactive lever responses at the post-
acquisition time point, strain was the only significant factor [F (2, 42) = 3.8, p<0.03, η2= 
0.2]. Pairwise comparisons revealed that SHR made a greater number of inactive lever 
responses than WKY (p<0.05) and that WIS did not differ significantly from either SHR or 
WKY (Table 1). When inactive lever responses were analyzed as a percentage of all 
responses, no significant strain or treatment differences were revealed (Table 1).
Experiment 2: Cocaine dose-response functions under the fixed ratio schedule
Analysis of the number of cocaine infusions during dose-response testing under FR1 (Figure 
2) identified differences in strain [F (2, 40) = 36.3, p<0.001, η2=0.6] and dose [F (5, 200) = 
87, p<0.001, η2= 0.6], as well as strain × treatment [F (2, 40) = 3.9, p<0.03, η2=0.06], strain 
× dose [F (10, 200) = 8, p<0.001, η2=0.1], and strain × treatment × dose [F (10, 200) = 2.5, 
p<0.007, η2=0.03] interactions. The main effect of treatment (p<0.21) and the treatment × 
dose interaction (p<0.84) did not reach statistical significance. Based on pairwise 
comparisons, SHR earned a greater number of infusions at 0.003, 0.01, 0.03 and 0.1 mg/kg 
cocaine than WKY and WIS (ps<0.001), and a greater number of infusions at 0.3 mg/kg 
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cocaine than WKY (p<0.006). WIS earned a greater number of infusions at 0.1 mg/kg 
cocaine than WKY (p<0.004). After adolescent AMPH treatment, adult WIS earned fewer 
infusions at 0.1 and 0.3 mg/kg cocaine compared to VEH (p<0.001 and 0.01, respectively). 
Adolescent AMPH treatment did not significantly alter the number of infusions earned 
compared to VEH at any cocaine dose in adult SHR or WKY.
Analysis of total active lever responses during dose-response testing under FR1 (Table 2) 
identified differences in strain [F (2, 40) = 30.1, p<0.001, η2=0.6] and dose [F (5, 200) = 
50.3, p<0.001, η2=0.5], as well as a strain × dose interaction [F (10, 200) = 7.1, p<0.001, 
η2=0.1]. Pairwise comparisons revealed that SHR made a greater number of active lever 
responses than WKY and WIS for 0.003, 0.01, 0.03 and 0.1 mg/kg cocaine (ps<0.001). The 
treatment main effect (p<0.09), and the strain × treatment (p<0.07) and strain × treatment × 
dose (p<0.09) interactions did not reach statistical significance, though WIS appeared to 
make fewer active lever responses for 0.1 and 0.3 mg/kg cocaine after adolescent AMPH 
than VEH (see below). Analysis of active lever responses during the timeout period (Table 
2) also revealed strain [F (2, 40) = 13.4, p<0.001, η2=0.4] and dose [F (5, 200) = 18.9, 
p<0.001, η2=0.3] differences, as well as a strain × dose interaction [F (10, 200) = 3.8, 
p<0.001, η2=0.1]. There was no significant influence of treatment, either as a main effect 
(p<0.18) or as an interaction with strain and/or dose (ps<0.43-0.99). Pairwise comparisons 
revealed that SHR made more timeout responses on the active lever than WKY and WIS for 
0.003, 0.01, 0.03, and 0.1 mg/kg cocaine (ps<0.04, except vs. WIS at 0.003 where p<0.07). 
WIS also made more timeout responses on the active lever than WKY for 0.1 mg/kg cocaine 
(p<0.002). Analysis of total inactive lever responses during dose-response testing under FR1 
(Table 2) revealed only a strain difference [F (2, 40) = 4.3, p<0.02, η2=0.03]. Pairwise 
comparisons revealed that SHR made a greater number of inactive lever responses than 
WKY (p<0.02), and that WIS did not differ significantly from either SHR or WKY. When 
inactive lever responses were analyzed as a percentage of all responses, no significant strain, 
treatment or dose differences were revealed (Table 2).
It is possible that the greater amount of cocaine self-administered by SHR relative to WKY 
and WIS may have impacted the results of FR dose-response testing. To rule this out, we 
performed analysis of covariance (ANCOVA) on infusions and active lever responses, with 
baseline cocaine intake at the acquisition criterion as the covariate. The significant ANOVA 
factors reported above for each measure remained significant in the ANCOVA 
(ps<0.001-0.045), indicating that baseline cocaine intake does not account for the strain, 
treatment and dose differences under FR dose-response testing. An additional feature 
revealed by the ANCOVA was a significant strain × treatment × dose interaction for active 
lever responses [F (10, 195) = 2.0, p<0.032]. Confirming previous trends in the data, further 
analysis with pairwise comparisons indicated that when baseline cocaine intake was taken 
into consideration, adult WIS treated with adolescent AMPH made fewer active lever 
responses maintained by 0.1 (p<0.001) and 0.3 (p<0.05) mg/kg cocaine compared to VEH-
treated WIS.
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Experiment 3: Cocaine dose-response functions under the progressive ratio schedule
Analysis of the primary measure of PR breakpoint (number of infusions) over a range of 
cocaine doses (Figure 3a) revealed differences in strain [F (2, 37) = 43.6, p<0.001, η2=0.6], 
treatment [F (1, 37) = 5.8, p<0.02, η2=0.04], and dose [F (3, 111) = 120.4, p<0.001, 
η2=0.7], as well as treatment × dose [F (3, 111) = 3.4, p<0.02, η2=0.02] and strain × 
treatment × dose [F (6, 111) = 2.2, p<0.05, η2=0.03] interactions. The strain × treatment 
(p<0.07) and strain × dose (p=0.69) interactions did not reach statistical significance. 
Pairwise comparisons revealed that, overall, SHR had higher breakpoints (more infusions) 
than WKY and WIS across all cocaine doses (ps<0.001). Pairwise comparisons for 
treatment revealed that breakpoints were lower (fewer infusions) after adolescent AMPH 
than VEH at 0.3 and 1.0 mg/kg cocaine (p<0.05 and 0.01, respectively). When treatment 
was analyzed by dose and strain, breakpoints at 0.3 and 1.0 mg/kg cocaine were lower after 
adolescent AMPH than VEH only in adult WIS (p<0.003 and 0.001, respectively). 
Compared to VEH, adolescent AMPH did not significantly alter breakpoint at any cocaine 
dose in adult WKY or SHR.
Analyses of the secondary measure of PR breakpoint (last FR completed) over a range of 
cocaine doses (Figure 3b) revealed differences in strain [F (2, 37) = 42.6, p<0.001, η2=0.6] 
and dose [F (3, 111) = 71.6, p<0.001, η2=0.6], as well as a strain × dose interaction [F (6, 
111) = 6.5, p<0.001, η2=0.1]. The main effect of treatment (p<0.08) and the strain × 
treatment (p<0.37), treatment × dose (p<0.24), and strain × treatment × dose (p<0.17) 
interactions did not reach statistical significance. Pairwise comparisons revealed that, 
overall, SHR had higher breakpoints (larger last FR completed) than WKY and WIS across 
all cocaine doses (ps<0.001, except for 0.01 mg/kg where ps<0.05).
Analysis of total active lever responses under the PR schedule (Table 3) revealed differences 
in strain [F (2,37) = 39, p<0.001, η2=0.6] and dose [F (3, 111) = 62.7, p<0.001, η2=0.5] as 
well as a strain × dose interaction [F (6, 111) = 6.3, p<0.001, η2=0.1]. The main effect of 
treatment (p<0.09) and the strain × treatment (p<0.36), treatment × dose (p<0.23), and strain 
× treatment × dose (p<0.16) interactions did not reach statistical significance. Pairwise 
comparisons revealed that, overall, SHR made more active lever responses than WKY and 
WIS (all dose ps<0.001, except for 0.01 mg/kg where ps<0.06). Analysis of total inactive 
lever responses under the PR schedule (Table 3) revealed only a main effect of cocaine dose 
[F (3, 111) = 2.6, p<0.05, η2=0.06], although pairwise comparisons did not detect any 
significant between-dose differences. Additionally, when inactive lever responses were 
analyzed as a percentage of all responses, there were no significant strain, treatment or dose 
differences revealed (Table 3).
To ascertain whether the greater amount of cocaine self-administered by SHR relative to 
WKY and WIS at baseline could have impacted the results of PR dose-response testing, we 
performed ANCOVA on infusions, last FR completed, and active lever responses. The 
significant ANOVA factors reported above for each measure remained significant in the 
ANCOVA (ps<0.001-0.019), indicating that baseline cocaine intake does not account for the 
strain, treatment and dose differences under PR dose-response testing.
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Discussion
Strain differences in cocaine abuse vulnerability
Adult SHR acquired cocaine self-administration faster and, at the post-acquisition time 
point, earned more cocaine infusions and made more active lever responses than adult WKY 
and WIS control strains. SHR also earned more infusions and made more active lever 
responses during cocaine dose-response testing under FR and PR schedules relative to WKY 
and WIS, indicating that cocaine functioned as a reinforcer to a greater degree in SHR. 
These findings replicate our prior studies using SHR (Baskin et al. 2015; Harvey et al. 2011; 
Jordan et al. 2014; Somkuwar et al. 2013b), and are consistent with increased cocaine abuse 
vulnerability reported in adolescents and adults with ADHD (Lee et al. 2011).
In the current study, the ratio of active lever responses to cocaine infusions under the FR1 
schedule was greater than 1:1 in all strains due to the 20-s timeout period that followed each 
cocaine infusion. During the timeout periods, animals could respond on the active lever, but 
additional cocaine infusions could not be earned. Increased active lever responding during 
the timeout period could represent a loss of stimulus control or a generalized activity-
enhancing effect (Spealman and Goldberg 1978), particularly in SHR who made 
significantly more timeout responses on the active lever than WKY and WIS. The greater 
number of inactive lever responses under the FR 1 schedule in SHR compared to WKY 
and/or WIS also suggests a potential loss of stimulus control in SHR. However, when 
inactive responses were analyzed as a percentage of total lever responses, no significant 
strain, treatment or dose differences were observed, suggesting stimulus control was 
relatively intact in SHR. Importantly, the timeout period was signaled by illumination of a 
stimulus light above the active lever. Thus, the increase in active lever responses in SHR 
during the timeout period may represent increased cocaine-seeking behavior and reflect a 
greater degree of reactivity to cocaine-paired cues, rather than loss of stimulus control. 
Previously, SHR were shown to be more reactive to cocaine-paired cues than WKY or WIS 
strains under a second-order schedule of cocaine delivery (Jordan et al. 2014; 2016). To the 
best of our knowledge, no studies have examined cocaine cue reactivity in ADHD patients, 
but our findings in SHR suggest that this may be an important clinical question to pursue for 
understanding the association of ADHD with heightened cocaine abuse vulnerability (Lee et 
al. 2011).
One criticism against using WKY as a control for the SHR model of ADHD has been that 
WKY are hypoactive relative to other strains (Ferguson and Cada, 2003). Indeed, we found 
that WKY display less open field activity than SHR and WIS (Somkuwar et al. 2016). 
However, in the current work assessing cocaine abuse vulnerability, VEH-treated WKY and 
WIS did not significantly differ on any measure of cocaine self-administration, with the 
exception of differences in cocaine intake at the post-acquisition time point and at the 0.1 
mg/kg cocaine dose under the FR1 schedule. These results oppose the possibility that WKY 
hypoactivity influenced our interpretation concerning cocaine abuse vulnerability in SHR. 
Nonetheless, differences in WKY and WIS activity levels emphasize the importance of 
concurrent evaluation of both WKY and an outbred control strain when evaluating the SHR 
as a model of ADHD.
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Effects of adolescent d-amphetamine treatment on cocaine abuse vulnerability: potential 
mechanisms
As hypothesized, adolescent AMPH treatment did not increase cocaine self-administration 
behaviors in SHR. Adolescent AMPH was protective to varying degrees in SHR and WIS. In 
adult SHR, adolescent AMPH reduced post-acquisition cocaine intake, but there were no 
significant differences in the rate at which VEH- and AMPH-treated SHR acquired cocaine 
self-administration. This lack of a treatment finding for the rate of acquisition of cocaine 
self-administration in SHR may represent a floor effect, as a minimum of 2 days were 
required to reach acquisition criterion. However, subsequent testing showed that AMPH 
treatment did not significantly alter cocaine intake under FR and PR schedules in SHR, 
suggesting that adolescent AMPH treatment does not further increase cocaine self-
administration in this strain. We previously showed that adolescent AMPH treatment 
reduced cue-induced reinstatement of cocaine-seeking responses during the first of seven 
test sessions in adult SHR (Jordan et al. 2016). Effects of adolescent treatment with the non-
stimulant ADHD medication, atomoxetine (a selective NET inhibitor; Bymaster et al. 2002), 
were similar to AMPH in adult SHR, except that cocaine-seeking responses were reduced 
across the seven reinstatement test sessions (Jordan et al. 2014). These findings contrast with 
the effects of adolescent methylphenidate treatment, which augmented the rate of acquisition 
of cocaine self-administration, the reinforcing effects of cocaine under FR and PR schedules, 
and cocaine intake under a second-order schedule of reinforcement in adult SHR (Baskin et 
al. 2015; Harvey et al. 2011; Jordan et al. 2014).
One reason why adolescent AMPH and methylphenidate treatment may differ in their effects 
on cocaine self-administration is through different long-term effects on DAT. Unlike 
methylphenidate, AMPH can be taken up into the cell through monoamine transporters, 
where it inhibits VMAT-2 and also binds to the intracellular trace amine-associated receptor 
1 (TAAR1), which is co-localized with DAT (Lindemann et al. 2008; Xie et al. 2007). 
Activation of TAAR1 by AMPH reduces cell surface expression of DAT, and may decrease 
DAT function (Miller, 2011; Xie and Miller, 2009). Therefore, whereas adolescent 
methylphenidate treatment increases DAT function in mPFC of SHR (Somkuwar et al. 
2013a), adolescent AMPH treatment may reduce DAT expression and function. Although 
effects of adolescent AMPH on mPFC DAT in SHR are not yet confirmed, acute AMPH 
infusions reduce DAT function and expression in the nucleus accumbens of adult outbred 
rats (Ferris et al. 2015). It is also worth noting that adolescent atomoxetine treatment did not 
increase DAT function in mPFC of adult SHR, but rather reduced DAT function in 
orbitofrontal cortex of adult SHR (Somkuwar et al. 2013b). A decrease in DAT function may 
lead to slower clearance of dopamine and higher basal dopaminergic tone in the synapse 
(Zahniser and Sorkin, 2004). When cocaine is self-administered under these conditions, 
post-synaptic responses to phasically released dopamine could therefore be reduced (Grace, 
2001), leading to a diminished reinforcing effect of cocaine. Notably, neither our previous 
work (Harvey et al., 2011; Somkuwar et al., 2013) nor work by other laboratories (e.g., 
Womersley et al. 2011) have demonstrated differences in DAT function or expression in 
SHR vs. WKY or WIS control in other brain regions, such as the striatum. Although long-
term changes in DAT function following adolescent ADHD medication have not yet been 
documented outside mPFC or orbitofrontal cortex (OFC), these regions are among the 
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primary loci of dysfunction in ADHD as well as in substance use disorders (e.g., Cubillo et 
al. 2011; Hester and Garavan, 2004). Medication-induced changes in these regions may have 
important implications for the long-term course of these disorders.
Surprisingly, adolescent AMPH treatment had robust protective effects on cocaine self-
administration in adult WIS. In this outbred control strain, adolescent AMPH not only 
reduced cocaine intake at the acquisition criterion, but also slowed the rate to acquire 
cocaine self-administration and produced downward shifts in cocaine dose-response curves 
for cocaine intake under FR and PR schedules in adulthood. Notably, these effects were 
observed months after discontinuation of AMPH treatment. Downward shifts reflect a 
reduced vulnerability to the reinforcing value of cocaine (Piazza et al. 2000). In a previous 
report, adolescent methylphenidate slowed the rate of acquisition of cocaine self-
administration in adult WIS, but did not significantly alter cocaine dose-response functions 
under FR and PR schedules in adult WIS (Harvey et al. 2011). Interestingly, adolescent 
methylphenidate decreased the affinity of DAT for dopamine in OFC of adult WIS, but did 
not alter DAT function in mPFC in this strain (Somkuwar et al. 2013b). If adolescent AMPH 
treatment reduces DAT function, this may contribute to the drug’s protective effects against 
cocaine self-administration in adult WIS.
In contrast to the beneficial effects of adolescent AMPH on cocaine self-administration in 
SHR and WIS, this treatment increased the rate of acquisition of cocaine self-administration 
in adult WKY, similar to adolescent atomoxetine in adult WKY (Somkuwar et al. 2013b). 
Conversely, adolescent methylphenidate did not alter the rate of acquisition of cocaine self-
administration in adult WKY (Harvey et al. 2011). It is worth noting that WKY exhibit a 
number of behavioral and neurochemical abnormalities that may represent a depressive/
anxiety-prone phenotype (De La Garza and Mahoney, 2004; Pardon et al. 2002; Paré et al. 
1997; Scholl et al. 2010), including decreased DAT density in the nucleus accumbens (Jiao 
et al. 2003). Consistent with the proposed role of DAT in cocaine abuse vulnerability, 
adolescent atomoxetine treatment increased, whereas adolescent methylphenidate decreased, 
DAT function in OFC of adult WKY (Somkuwar et al. 2013a, b). If the effects on DAT 
resulting from adolescent AMPH resemble those of atomoxetine in WKY, AMPH may 
produce increases in DAT function in OFC, and thereby, potentially augment the reinforcing 
value of cocaine in this strain to increase the rate of acquisition of cocaine self-
administration.
Implications
In concurrence with observations of elevated cocaine use among individuals with ADHD 
(Lee et al. 2011), the current report demonstrates elevated cocaine self-administration 
behaviors in the SHR on measures that model the early phases of cocaine abuse, and which 
are thought to identify phenotypes that are most vulnerable to the transition to compulsive 
drug use and dependence (Piazza et al. 2000). Importantly, adolescent AMPH treatment did 
not augment cocaine self-administration behaviors in adult SHR. These results stand in 
contrast to the results observed following discontinuation of adolescent methylphenidate 
treatment in adult SHR (Harvey et al. 2011). Given the different long-term consequences of 
AMPH vs. methylphenidate in the SHR model of ADHD, it does not appear to be 
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meaningful going forward to continue grouping stimulant drugs into a single medication 
variable in clinical studies seeking to elucidate relationships between ADHD, stimulant 
medications and SUD. Currently, 20% of teenage boys and 10% of teenage girls in the 
United States are diagnosed with ADHD (Visser et al. 2014). Approximately 20% of these 
teens receive a first-time ADHD diagnosis between ages 11–17, representing an estimated 
700,000 individuals (National Survey of Children’s Health 2011/2012). The current study 
employed males only, which is a limitation because ADHD diagnosis in teenage girls also is 
escalating. In the future, it is imperative that the long-term impact of ADHD medications on 
SUD is determined in females as well as in males, particularly because women with ADHD 
may have a higher risk of substance use disorders than men with ADHD (Dalsgaard et al. 
2014). Female SHR may represent an optimal preclinical model in which to investigate sex 
differences in the sensitivity and vulnerability to drug abuse (Bayless et al. 2015; Berger and 
Sagvolden 1998; Cailhol and Mormède, 1999; Vendruscolo et al. 2009).
The current work is the first to suggest that adolescent treatment with AMPH may prevent 
later cocaine abuse vulnerability in non-ADHD populations at risk for SUDs, as evidenced 
by findings in outbred WIS rats after discontinuing adolescent treatment. Interestingly, 
amphetamines show promise in the treatment of cocaine abuse. For example, in outbred rats 
with cocaine self-administration experience, concurrent AMPH produced downward shifts 
in cocaine dose-response functions (Chiodo et al. 2008; Zimmer et al. 2014), and reversed 
cocaine-induced deficits in DAT expression and function (Ferris et al. 2015). Similarly, in 
non-human primates, concurrent AMPH reduced cocaine self-administration under PR and 
second-order schedules of reinforcement, and increased choice for food over cocaine (Czoty 
et al. 2010; Negus 2003). In cocaine-abusing individuals, moderate doses of AMPH reduced 
cocaine intake and craving and improved treatment retention (Grabowski et al. 2001, 
Mooney et al. 2009). Amphetamines are effective also in reducing cocaine use and 
improving ADHD symptoms for adults with comorbid ADHD and cocaine use disorder 
(Levin et al. 2015). In contrast, methylphenidate is less effective in stimulant-dependent 
ADHD patients, possibly because of limited efficacy at DAT as a result of long-term 
stimulant abuse (Crunelle et al. 2013; Konstenius et al. 2010).
Preventative measures recently have received attention as potentially more effective ways to 
reduce the prevalence of cocaine use disorder (e.g., Stanis and Andersen, 2014). Early 
adolescence may represent an optimal period in which to implement preventative measures 
for SUD, as drug use before age 14 is associated with a four-fold greater risk of developing 
SUD (SAMHSA, 2006). The current findings suggest that adolescent AMPH treatment may 
be one viable measure for reducing future cocaine abuse risk in individuals with and without 
ADHD. However, caution is warranted given the differential effects of adolescent AMPH 
treatment in SHR and WIS vs. WKY during acquisition of cocaine self-administration. The 
long-term consequences of treatment with AMPH during adolescence could be favorable 
(SHR and WIS) or unfavorable (WKY) in individuals expressing different behavioral and 
neurochemical phenotypes.
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Fig. 1. 
Mean (± SEM) number of sessions required to reach criterion for acquisition of cocaine self-
administration (a), and number of post-acquisition cocaine infusions (b). Experiments were 
performed in adult WKY, WIS, and SHR following vehicle (VEH) or d-amphetamine 
(AMPH) treatment during adolescence. Group sizes are n=8 per strain and treatment group. 
* p<0.05 compared to WKY and WIS overall (main effect of strain). ** p<0.05 compared to 
WKY overall (main effect of strain). ^ p<0.05 compared to VEH in the same strain.
Jordan et al. Page 19
Psychopharmacology (Berl). Author manuscript; available in PMC 2017 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 2. 
Cocaine dose-response functions based on the mean ± SEM number of infusions earned 
under a fixed ratio 1 (FR1) schedule of reinforcement. Experiments were performed in adult 
WKY, WIS, and SHR following vehicle (VEH) or d-amphetamine (AMPH) treatment during 
adolescence. Group sizes are n=8 for VEH and AMPH-treated WKY and WIS, and n=7 for 
VEH and AMPH-treated SHR. * p<0.05 compared to WKY and WIS overall (mai effect of 
strain). ** p<0.05 compared to WKY overall (main effect of strain). ^ p<0.05 compared to 
VEH in the same strain.
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Fig. 3. 
Cocaine dose-response functions based on the mean ± SEM number of infusions earned (a) 
and last FR completed (b) under a progressive ratio (PR) schedule of reinforcement. 
Experiments were performed in adult WKY, WIS, and SHR following vehicle (VEH) or d-
amphetamine (AMPH) treatment during adolescence. Group sizes are n=8 for VEH and 
AMPH-treated WIS, n=7 for VEH and AMPH-treated WKY and VEH-treated SHR, and 
n=6 for AMPH-treated SHR. * p<0.05 compared to WKY and WIS overall (main effect of 
strain). ^ p<0.05 compared to VEH in the same strain.
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Table 1
Lever responses at the post-acquisition time point.
Strain Treatment Active Lever Inactive Lever
Total Responses Timeout Responses Total Responses % of All Responses
WKY
VEH 28.3 (± 2.4) 2.4 (± 1.1) 2.1 (± 0.5) 7.5% (± 1.8)
AMPH 31.4 (± 1.5) 4.4 (± 1.3) 4.0 (± 1.1) 13.3% (± 3.9)
WIS
VEH 67.4 (± 13.1) 14.4 (± 8.3) 3.3 (± 0.9) 7.4% (± 3.1)
AMPH 38.9 (± 9.4) 8 (± 2.8) 3.6 (± 1.6) 11.7% (± 5)
SHR
VEH 125.0 (± 29.5) * 59.3 (± 24.9)* 11.5 (± 5.2) ** 11.7% (± 4.5)
AMPH 63.4 (± 8.6) * ^ 16.8 (± 4.9)* 9.3 (± 4.7) ** 12.0% (± 4.8)
Mean (± SEM) active and inactive lever responses. Inactive lever responses expressed as the percentage of all responses were calculated for each 
animal and then averaged across the group. Group sizes are n=8 per strain and treatment group.
*p<0.05 compared to WKY and WIS overall (main effect of strain).
**p<0.05 compared to WKY overall (main effect of strain).
^p<0.05 compared to VEH in the same strain.
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Table 2
Lever responses for fixed ratio dose-response functions.
Group Cocaine Dose
(mg/kg)
Active Lever Inactive Lever
Total Responses Timeout Responses Total Responses % of All Responses
WKY
VEH
0.003 12.6 (± 2) 2.5 (± 0.6) 9.9 (± 2.8) 41.6% (± 5.6%)
0.01 21.8 (± 4.2) 6.1 (± 1.9) 10.2 (± 2.9) 31.4% (± 4.3%)
0.03 49.2 (± 6.7) 12.1 (± 2.3) 15.7 (± 3.3) 24.0% (± 2.8%)
0.1 74.1 (± 20.8) 16.5 (± 6.3) 9.6 (± 3) 15.6% (± 4.8%)
0.3 31.6 (± 2.3) 5.1 (± 1.6) 4.6 (± 1.5) 11.7% (± 3.3%)
1.0 15.5 (± 2.3) 2.1 (± 0.5) 4.2 (± 1.1) 20.6% (± 5.2%)
WKY
AMPH
0.003 18.4 (± 3.6) 4.7 (± 1.6) 10.8 (± 2.3) 41.3% (± 5.8%)
0.01 27.9 (± 6.3) 6.6 (± 2.3) 12.1 (± 4.4) 36.6% (± 7%)
0.03 66.8 (± 15.6) 15.6 (± 4.2) 18.1 (± 7.2) 25.9% (± 6%)
0.1 97.9 (± 18.7) 28 (± 10) 11.9 (± 3.9) 14.4% (± 3.7%)
0.3 43 (± 3.3) 5.7 (± 1.5) 4.4 (± 1.5) 11.1% (± 3.8%)
1.0 19.9 (± 2.1) 2.4 (± 1.1) 3.5 (± 1.1) 16.0% (± 4.3%)
WIS
VEH
0.003 22.9 (± 5.2) 7.2 (± 2.7) 23.0 (± 4.2) 56.9% (± 6%)
0.01 29.1 (± 7.9) 8.4 (± 3.2) 21.1 (± 5.1) 52.8% (± 6.5%)
0.03 66.4 (± 26.5) 23.9 (± 12.4) 30.6 (± 11.5) 38.6% (± 9.6%)
0.1 208.5 (± 45.4) 80.9 (± 32.1)** 31.6 (± 21.1) 15.6% (± 7.3%)
0.3 95.5 (± 28.3) 33.4 (± 25.5) 23.9 (± 13.6) 17.4% (± 8.3%)
1.0 54.7 (± 23.7) 29 (± 21.3) 10.9 (± 8) 17.0% (± 7.2%)
WIS
AMPH
0.003 15.8 (± 3.6) 5.1 (± 1.8) 8.2 (± 2.9) 34.1% (± 6.3%)
0.01 17.3 (± 3.9) 6.3 (± 2.1) 13.8 (±3.3) 50.9% (± 7.9%)
0.03 40.1 (± 16.9) 16.1 (± 6.9) 20.4 (± 7.6) 42.7% (± 5.5%)
0.1 89.3 (± 31.3) ^ 57.5 (23.8)** 16.1 (± 8.2) 22.6% (± 6.5%)
0.3 35.8 (± 9.1) ^ 6.5 (± 2.1) 27.9 (± 23.9) 25.2% (± 9.4%)
1.0 15.5 (± 3.6) 2.4 (± 1.1) 19.9 (± 7.2) 48.0% (± 7.9%)
SHR
VEH
0.003 106.6 (± 11.8) * 45.3 (± 9.2)** 40.1 (± 8.9) ** 39.4% (± 8.3%)
0.01 128.5 (± 20.6) * 52.7 (± 13.8)* 47.3 (± 12.8) ** 37.8% (± 7.4%)
0.03 197.5 (± 29.1) * 81 (± 12.9)* 40.0 (± 8.5) ** 28.4% (± 7.9%)
0.1 275.1 (± 53.2) * 130.2 (47)* 183.6 (± 164.9) ** 23.3% (± 11.4%)
0.3 83.9 (± 9.2) 24.7 (± 7.2) 64.5 (± 46.4) ** 27.6% (± 12.2%)
1.0 36.6 (± 3.7) 10.7 (± 2.1) 97.1 (± 44.1) ** 45.5% (± 16.2%)
SHR
AMPH
0.003 87.1 (± 12.5) * 29.6 (± 4.3)** 26.1 (± 6.8) ** 32.0% (± 5.4%)
0.01 96.4 (± 13.6) * 35.5 (± 4.2)* 26.2 (± 6.3) ** 32.1% (± 8.3%)
0.03 143.4 (± 37.1) * 47.7 (± 12.6)* 21.9 (± 5.4) ** 21.7% (± 5%)
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Group Cocaine Dose
(mg/kg)
Active Lever Inactive Lever
Total Responses Timeout Responses Total Responses % of All Responses
0.1 275.4 (± 48.2) * 117.2 (± 41.3)* 56.8 (± 46.2) ** 15.5% (± 9.1%)
0.3 81.3 (± 7.2) 15.2 (± 3.9) 8.0 (± 3.5) ** 9.9% (± 3.8%)
1.0 37.2 (± 7.7) 11.6 (± 6.5) 98.0 (± 93.5) ** 25.2% (± 12.9%)
Mean (± SEM) active and inactive lever responses. Inactive lever responses expressed as the percentage of all responses were calculated for each 
animal, and then averaged across the group. Group sizes are n=8 for VEH and AMPH-treated WKY and WIS, and n=7 for VEH and AMPH-treated 
SHR.
*p<0.05 compared to WKY and WIS overall (strain × dose interaction).
**p<0.05 compared to WKY overall (strain × dose interaction).
^p<0.05 compared to VEH in the same strain.
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Table 3
Lever responses for progressive ratio dose-response functions.
Group Cocaine Dose
(mg/kg)
Active Lever Inactive Lever
Total Responses Total Responses % of All Responses
WKY
VEH
0.01 25.4 (± 10.4) 8.5 (± 5.3) 20.8% (± 4.3%)
0.1 78.8 (± 15.8) 7.1 (± 3.1) 8.2% (± 2.5%)
0.3 189.1 (± 60.3) 9.9 (± 4.3) 6.3% (± 2.7%)
1.0 413.6 (± 111.2) 17.6 (± 7.6) 5.1% (± 1.9%)
WKY
AMPH
0.01 46.6 (± 13.4) 5.7 (± 0.6) 17.3% (± 5.3%)
0.1 67.4 (± 16.4) 3.5 (± 1.3) 7.7% (± 4.2%)
0.3 182.7 (± 76.1) 4.9 (± 2.1) 4.8% (± 2.3%)
1.0 297.5 (± 94.9) 5.8 (± 2.7) 5.8% (± 4.3%)
WIS
VEH
0.01 51.5 (± 11) 16.1 (± 2.6) 26.9% (± 5.6%)
0.1 122 (± 37.4) 23.8 (± 3) 20.8% (± 3.2%)
0.3 299.4 (± 62.6) 47.8 (± 13) 15.3% (± 3.3%)
1.0 696.1 (± 177.3) 84.4 (± 18.5) 13.5% (± 3.6%)
WIS
AMPH
0.01 30.3 (± 11.9) 6.4 (± 1.9) 18.3% (± 5.5%)
0.1 56.3 (± 18.1) 12.4 (± 4.6) 17.8% (± 5.1%)
0.3 99.1 (± 40.1) 21.3 (± 9.9) 13.8% (± 4.3%)
1.0 219.3 (± 88.5) 47.4 (± 26.1) 10.5% (± 3.9%)
SHR
VEH
0.01 296.5 (± 35.9) 39.2 (± 12.6) 10.9% (± 3.7%)
0.1 557.7 (± 95.8) * 77 (± 26.8) 12.1% (± 4.2%)
0.3 826.4 (± 93.1) * 127.7 (± 48.1) 13.1% (± 5.2%)
1.0 1115 (± 101) * 448.8 (± 342) 17.8% (± 9.8%)
SHR
AMPH
0.01 195.5 (± 18.7) 31.9 (± 13.5) 13.1% (± 4.8%)
0.1 476.6 (± 55) * 27.2 (± 11.9) 5.6% (± 2.2%)
0.3 789 (± 168) * 35.7 (± 10.7) 4.7% (± 1.6%)
1.0 1140 (± 271) * 66.1 (± 45.9) 3.8% (± 1.6%)
Mean (± SEM) active and inactive lever responses. Inactive lever responses expressed as the percentage of all responses were calculated for each 
animal, and then averaged across the group. Group sizes are n=8 for VEH and AMPH-treated WIS, n=7 for VEH and AMPH-treated WKY and 
VEH-treated SHR, and n=6 for AMPH-treated SHR.
*p<0.05 compared WKY and WIS overall (strain × dose interaction).
Psychopharmacology (Berl). Author manuscript; available in PMC 2017 December 01.
